A wrist-worn medical device — called the Personal KinetiGraph or PKG — that reminds people with Parkinson’s disease to take their medication, and records their movements to provide physicians with objective measurements of motor symptoms, showed great promise as a tool to improve clinical decision-making, a study found. Read full article here
News & Events
Global Kinetics Corporation Ltd. today announced the publication of a study demonstrating that the use of data from its wearable FDA-cleared Personal KinetiGraph® (PKG®) provides an objective and more effective approach to assessing motor fluctuations in Parkinson’s Disease (PD) patients compared with patient-reported motor diaries. Study results were published in Functional Neurology.1
Read press release here
Global Kinetics’ Personal KinetiGraph (PKG) wearable sensor system can identify the best candidates for device-assisted therapies for Parkinson’s disease, including deep brain stimulation, more efficiently than clinical assessment alone, according to new study results.
Read full article here...
Novel screening tool provides first objective assessment for managing referral for device-assisted therapy (DAT), including deep brain stimulation (DBS) and infusion therapies, and has potential to improve management of Parkinson’s Disease
Global Kinetics Corporation Ltd. today announced the publication of a study demonstrating that the use of data from its wearable FDA-cleared watch, the Personal KinetiGraph® (PKG®), can provide an objective approach to identifying Parkinson’s Disease (PD) patients who may be candidates for device-assisted therapies (DAT) such as deep brain stimulation (DBS).
Read full press release here
Read published paper
Data Recently Presented at the 2019 American Academy of Neurology’s Annual Meeting APPRISE Clinical Study Continues Enrollment at 10 Movement Disorder Clinics in the U.S.
Global Kinetics today reported data that was recently presented at poster presentation sessions during the 2019 American Academy of Neurology’s (AAN) Annual Meeting in Philadelphia, PA, May 4 – 10, 2019 and the 2019 Parkinson Study Group (PSG) in Phoenix, AZ, April 5 – 8, 2019. The two posters highlighted how the Company’s Personal KinetiGraph®(PKG®) technology provided clinically meaningful improvements in Parkinson’s disease (PD) symptom assessment, management and medication optimization, and also enhanced patient-clinician conversations.
Read the press release here